An ongoing dialogue on HIV/AIDS, infectious diseases,
March 10th, 2009
Unwelcome Visitor: Cost of HIV Meds
Those of us who practice HIV medicine in Taxachusetts (warning, click link at your peril) live a pretty charmed life, at least so far as getting HIV medications paid for. Due to an incredibly generous AIDS Drug Assistance Program (ADAP), rare is the patient who faces financial barriers getting his or her drugs.
(By the way, we abbreviate it “HDAP” here, not ADAP. And we treat early syphilis with two shots of penicillin, not one. And we voted for McGovern. And we drive on the left.)
But the recent downturn in the economy has changed this usually comfortable situation in the Bay State.
A patient of mine called to tell me that his co-pay for a 3 month supply of his antivirals is now nearly $2000. Another one has simply stopped coming to appointments, as his wife’s insurance has such a large deductible that he will only agree to blood tests, not an actual office visit. A third asked me whether he would be better off stopping enoxaparin or his HIV meds, since he couldn’t afford both.
I am sure things are much worse in other States — after all, Houston’s Joe Gathe initially tried lopinavir/r monotherapy since he reasoned that some ART was better than none, and his patients couldn’t afford triple-therapy.
Where is this headed? It’s tough to make predictions (especially about the future), but I suspect that when 3TC and saquinavir become generic, we might be turning to them more often than we’d previously thought.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Subacute Sclerosing Panencephalitis after Measles Infection February 21, 2026A 7-year-old boy was brought to a hospital with a 3-month history of cognitive deterioration and seizures. He had contracted measles at 7 months of age while living in an area where the infection is endemic.
- AI-Enabled Precision-Education Systems — Transforming Lifelong Learning in Medicine February 21, 2026Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.
- Revival of Ethionamide by Alpibectir February 19, 2026Ethionamide has been used to treat tuberculosis for decades, but dose-dependent toxic effects have limited its use. In this trial, alpibectir enabled the ethionamide dose to be reduced by two thirds.
- Peritoneal Coccidioidomycosis February 19, 2026A 23-year-old man presented with a 2-month history of unintentional weight loss and worsening abdominal pain and distention. He had recently moved to Arizona from a remote Pacific island.
- Reducing Tobacco Use Worldwide: Tobacco Cessation among Nondaily and Low-Intensity Smokers — Challenges and Opportunities in Latin America February 19, 2026In Latin America, though overall smoking rates have declined, nondaily and low-intensity smoking are increasingly common, and tobacco-cessation resources remain underdeveloped in many countries.
- Subacute Sclerosing Panencephalitis after Measles Infection February 21, 2026